James Symanowski
Overview
Explore the profile of James Symanowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice?
Raghavan D, Symanowski J
JCO Oncol Pract
. 2025 Mar;
:OP2500117.
PMID: 40053893
No abstract available.
2.
Ghosh N, Matusz-Fisher A, Bose R, Boselli D, Magee G, Chen T, et al.
JCO Oncol Pract
. 2024 Nov;
:OP2400417.
PMID: 39556779
Purpose: Venetoclax has made a significant impact in the treatment of chronic lymphocytic leukemia (CLL) due to its ability to induce deep and durable remissions with a finite duration of...
3.
Grunwald M, Sha W, He J, Sanikommu S, Gerber J, Ai J, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1211.e1-1211.e11.
PMID: 39332808
Using haploidentical donors for allogeneic hematopoietic cell transplantation (HCT) broadens transplant accessibility to a growing number of patients with hematologic disorders. Moreover, haploidentical HCT with post-transplant cyclophosphamide (PTCy) has become...
4.
Nguyen D, Morris S, Hamilton A, Kwange S, Steuerwald N, Symanowski J, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2300623.
PMID: 38935897
Purpose: Fluoropyrimidine-related toxicity and mortality risk increases significantly in patients carrying certain genetic variants with standard dosing. We implemented genotyping at a multisite cancer center and evaluated its impact on...
5.
Brown L, Robinson M, McCormack M, Steuerwald N, Symanowski J, Sha W, et al.
Clin Genitourin Cancer
. 2024 May;
22(3):102086.
PMID: 38697880
Introduction: Men with advanced germ cell tumors (GCT) treated with chemotherapy are at high risk of venous thromboembolism (VTE). Predictors of VTE may identify patients who would benefit from prophylactic...
6.
Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, et al.
Ann Hematol
. 2024 Apr;
103(8):2837-2843.
PMID: 38662203
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin and/or hematocrit levels. Patients often have symptoms such as fatigue, pruritus, and...
7.
Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, et al.
J Clin Oncol
. 2023 Apr;
41(12):2125-2133.
PMID: 37068377
Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase...
8.
Osunkwo I, Lawrence R, Robinson M, Patterson C, Symanowski J, Minniti C, et al.
Contemp Clin Trials
. 2023 Jan;
126:107089.
PMID: 36669729
Background: Emerging adults with sickle cell disease (EASCD) experience significant challenges transitioning from pediatric to adult care. Acute care utilization increases, quality of life (QOL) declines, with an increased risk...
9.
Farhangfar C, Scarola G, Morris V, Farhangfar F, Dumas K, Symanowski J, et al.
JCO Clin Cancer Inform
. 2022 Jul;
6:e2200011.
PMID: 35839431
Purpose: Clinical trials of novel and targeted agents increasingly require biomarkers for eligibility. Precision oncology continues to evolve, but challenges hamper broad use of molecular profiling (MP) that could increase...
10.
Chojecki A, Arnall J, Boselli D, Patel R, Chiad Z, DiSogra K, et al.
Leuk Res
. 2022 Jun;
119:106904.
PMID: 35753088
No abstract available.